Latest Medications News
Bortezomib, which is used to treat cancer of the plasma cells, seems to target antibody-producing plasma cells that can cause organ rejection, according to the study, published in the Dec. 27 issue of the journal Transplantation.
"It has become clear that plasma cells and the antibodies they produce play a bigger role in rejection than previously thought, and the development of therapies targeting these cells has lagged," study lead author Dr. Steve Woodle, chief of transplant surgery at University of Cincinnati, said in a news release issued by the school. "We realized that current therapies don't target the plasma cells which may produce the antibody, in general," he said.
In the study, all six kidney transplant recipients with treatment-resistant organ rejection who received bortezomib experienced prompt rejection reversal, long-term reductions in antibody levels and improved organ function with suppression of recurrent rejection for at least five months.
The toxicities of bortezomib were at expected and manageable levels that were less than those of other anti-cancer agents, study co-author Jason Everly, an oncology pharmacist in the division of transplant surgery at UC, said in the same news release.
-- Kevin McKeever
SOURCE: University of Cincinnati, news release, Dec. 27, 2008
Copyright © 2008 ScoutNews, LLC. All rights reserved.
Subscribe to MedicineNet's General Health Newsletter